CSPC obtains clinical trial approval for diabetes treatment

CSPC Pharmaceutical Group Limited (HKEX:1093) announced that its prusogliptin and metformin extended-release tablets have received clinical trial approval from the National Medical Products Administration of the People's Republic of China. The treatment is designed as a fixed-dose combination therapy for type 2 diabetes. Prusogliptin is a dipeptidyl peptidase-IV (DPP-4) inhibitor, and metformin is a biguanide drug that enhances glucose tolerance. The clinical trial aims to assess the treatment as an adjunct to diet and exercise for adult patients with type 2 diabetes mellitus who have inadequate control with metformin alone or are receiving combination therapy. CSPC claims the product demonstrates a favorable safety and tolerability profile compared with monotherapy options, offering a promising clinical development value.